| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/02/2006 | US20060045885 Method of eliciting an immune response against HIV |
| 03/02/2006 | US20060045884 Vaccines for autoimmune and infectious disease |
| 03/02/2006 | US20060045883 Anti-cancer vaccines |
| 03/02/2006 | US20060045882 Developing oral tolerance for airborne allergens |
| 03/02/2006 | US20060045881 Anti-cancer vaccines |
| 03/02/2006 | US20060045880 Methods for modulating angiogenesis and apoptosis with apelin compositions |
| 03/02/2006 | US20060045879 Antibodies which are directed against the Marburg I polymorphism of factor VII-activating protease (FSAP), and their preparation and use |
| 03/02/2006 | US20060045878 Pancreas-derived plasminogen activator inhibitor |
| 03/02/2006 | US20060045877 Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| 03/02/2006 | US20060045876 Fusion proteins of humanized g250 specific antibodies and uses thereof |
| 03/02/2006 | US20060045853 Using tissue plasminogen activator finger domain specific immunolglobulins as tool in diagnosis of diabbetes and/or alzheimer's disease |
| 03/02/2006 | DE102005026163A1 Gegen den Marburg I Polymorphismus der Faktor VII aktivierenden Protease (FSAP) gerichtete Antikörper, ihre Herstellung und Verwendung Against the Marburg I polymorphism of the factor VII-activating protease (FSAP) Antibodies, their production and use |
| 03/02/2006 | DE102004031660A1 Agent to stimulate natural defenses against infection, in humans and/or mammals, is a microbial antigen-antitoxin combination in a variety of presentations |
| 03/02/2006 | CA2581173A1 Methods for treatment of angiogenesis |
| 03/02/2006 | CA2578361A1 Binding member towards pneumolysin |
| 03/02/2006 | CA2578021A1 Modified human hepatitis c virus genomic rna that can be autonomously replicated |
| 03/02/2006 | CA2577926A1 Nutritional composition comprising immunoglobulins and oligosaccharides |
| 03/02/2006 | CA2577631A1 Methods and compositions for treating allergic inflammation |
| 03/02/2006 | CA2577370A1 Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
| 03/02/2006 | CA2577329A1 Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| 03/02/2006 | CA2577188A1 Extended treatment of multiple sclerosis |
| 03/02/2006 | CA2576562A1 Nutritional composition comprising galactose-containing indigestible oligosaccharides |
| 03/02/2006 | CA2576500A1 Nucleic acids and corresponding proteins entitled 58p1d12 useful in treatment and detection of cancer |
| 03/02/2006 | CA2576247A1 Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, in staphylococcus aureus |
| 03/02/2006 | CA2574516A1 Vaccine composition against rhodococcus equi |
| 03/01/2006 | EP1630235A2 Compounds for immunodiagnosis of prostate cancer and method for their use |
| 03/01/2006 | EP1630230A2 Streptococcus pneumoniae proteins and nucleic acids |
| 03/01/2006 | EP1630229A2 Melanoma antigens |
| 03/01/2006 | EP1630172A2 A method for identification, isolation and production of antigens to a specific phathogen |
| 03/01/2006 | EP1630168A2 Molecular mimetics of meningococcal B peptides |
| 03/01/2006 | EP1629850A1 Nutritional composition comprising indigestible oligosaccharides |
| 03/01/2006 | EP1629281A2 Diagnostic method for atherosclerosis |
| 03/01/2006 | EP1629104A1 Cell surface expression vector of sars virus antigen and microorganisms transformed thereby |
| 03/01/2006 | EP1629013A1 Pharmaceutical composition comprising a bispecific antibody specific for epcam |
| 03/01/2006 | EP1629010A1 Treatment with anti-vegf antibodies |
| 03/01/2006 | EP1629005A2 Enterococcus antigens |
| 03/01/2006 | EP1629004A1 Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens |
| 03/01/2006 | EP1629002A1 Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines |
| 03/01/2006 | EP1629001A2 Blys antagonists and uses thereof |
| 03/01/2006 | EP1628991A2 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein |
| 03/01/2006 | EP1628687A2 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 03/01/2006 | EP1628683A2 Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
| 03/01/2006 | EP1628680A2 Hiv polynucleotides and polypeptides derived from botswana mj4 |
| 03/01/2006 | EP1628679A2 Compositions and methods for the diagnosis and treatment of tumors of glial origin |
| 03/01/2006 | EP1628675A2 Antigens targeted by prevalent pathogenic t cells in type 1 diabetes and uses thereof |
| 03/01/2006 | EP1628631A2 Methods of treating hyperproliferative cell disorders |
| 03/01/2006 | EP1628589A2 An improved method and apparatus for dosing single and multi-agent therapy |
| 03/01/2006 | EP1628530A2 Methods and compositions for the prevention and treatment of sepsis |
| 03/01/2006 | EP1537214B1 Regulated bacterial lysis for gene vaccine vector delivery and antigen release |
| 03/01/2006 | EP1290205B1 Duplexed parvovirus vectors |
| 03/01/2006 | EP1239875B1 Use of staphylococcal bacteria to treat irritable bowel syndrome |
| 03/01/2006 | EP1169465B1 Two-step immunization procedure against chlamydia infection |
| 03/01/2006 | EP1062517B1 Diagnosis of spongiform encephalopathies using prionins |
| 03/01/2006 | EP1049488B1 Method of and compositions for immunization with the pseudomonas aeruginosa v-antigen |
| 03/01/2006 | EP1038001B1 Constitutive expression of non-infectious hiv-like particles |
| 03/01/2006 | EP0998569B1 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
| 03/01/2006 | EP0956506B1 Treatment and diagnosis of cancer |
| 03/01/2006 | EP0941315B1 Fusion proteins containing stress proteins for inducing immune responses |
| 03/01/2006 | EP0932678B1 A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 03/01/2006 | EP0914346B1 THERAPEUTIC MULTISPECIFIC COMPOUNDS COMPRISED OF ANTI-FCalpha RECEPTOR ANTIBODIES |
| 03/01/2006 | EP0907735B1 Modulators of tissue regeneration |
| 03/01/2006 | EP0862634B2 Pharmaceutical composition for treating papillomavirus tumours and infection |
| 03/01/2006 | EP0840750B1 Ha-2 antigenic peptide |
| 03/01/2006 | EP0783526B1 Growth blocking agents to the vitamin b12 binding sites on transcobalamin ii |
| 03/01/2006 | EP0677105B1 Allergenic proteins and peptides from dog dander and uses therefor |
| 03/01/2006 | CN1742083A Immunizing fish against viral infection |
| 03/01/2006 | CN1742022A Neuropilin-1 inhibitors |
| 03/01/2006 | CN1742021A Therapeutic human anti-IL-1R1 monoclonal antibody |
| 03/01/2006 | CN1742019A Process for the preparation of hypoallergenic mosaic proteins |
| 03/01/2006 | CN1741818A 线虫多肽佐剂 Nematode peptide adjuvant |
| 03/01/2006 | CN1741817A A hepatitis c virus codon optimized non-structural NS3/4A fusion gene |
| 03/01/2006 | CN1741816A Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom |
| 03/01/2006 | CN1741815A 疟疾疫苗 Malaria Vaccine |
| 03/01/2006 | CN1740200A Cervical cancer inhibiting fusion protein |
| 03/01/2006 | CN1739802A Method of producing hepatitis B vaccine in non-human mammal mammary gland as bioreactor |
| 03/01/2006 | CN1739801A Influenza virus lysis vaccine and its prepn process |
| 03/01/2006 | CN1739800A Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 03/01/2006 | CN1739788A Modulation of TRIP-BR function and method of treating proliferative disorders |
| 03/01/2006 | CN1243569C Use of active P40 conjugates for nasal delivery |
| 03/01/2006 | CN1243568C Recombination protein for preventing human trachoma bedsnia infestation and its use |
| 02/28/2006 | US7005509 Pancreatic expressed chemokines, (PANEC-1); expression vectors, host cells, and diagnostic tests using probes for physiologic or pathologic compromise of the pancreas |
| 02/28/2006 | US7005498 analogues of immunogenic human Her2 proteins comprising amino acid sequences modified foreign T-helper lymphocyte epitopes, used for immunotherapy |
| 02/28/2006 | US7005285 Human p21-activated kinase 5 polypeptide |
| 02/28/2006 | US7005270 immunoassay of acidic repeat protein/immunogens; solid phase synthesis; kits for diagnosis of syphilis |
| 02/28/2006 | US7005262 Methods for detecting nucleic acids encoding human telomerase reverse transcriptase |
| 02/28/2006 | US7005141 Modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form drug containing microspheres. |
| 02/28/2006 | US7005131 Protective antigen of Epstein Barr Virus |
| 02/28/2006 | US7005130 Hepatitis virus for use in the diagnosis and prevention of viral diseases in birds and humans |
| 02/28/2006 | US7005129 Non-toxic mutants of pathogenic gram-negative bacteria |
| 02/28/2006 | CA2515158A1 Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease |
| 02/28/2006 | CA2486285A1 Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| 02/28/2006 | CA2180346C Herpesvirus pre-(viral dna replication) enveloped particles |
| 02/23/2006 | WO2006020706A2 Tie complex binding proteins |
| 02/23/2006 | WO2006020581A2 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 02/23/2006 | WO2006020266A2 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| 02/23/2006 | WO2006020258A2 Novel tetravalent bispecific antibody |
| 02/23/2006 | WO2006020071A2 Vaccines against aids comprising cmv/r-nucleic acid constructs |
| 02/23/2006 | WO2006019447A1 Optimized fc variants |
| 02/23/2006 | WO2006019427A2 Compositions and methods for prophylaxis, treatment and detection of malarial infections |
| 02/23/2006 | WO2006019183A1 Mucosal immunity and mucosal vaccine and protective inoculation system using the sensitizer |